Genocea Biosciences, Inc. GNCA
Set alert
0.00 0.00 0.00%
As of Dec 22, 2:54 PM ET
0.0001 Day range 0.0001
52-week range unavailable
- Open
- 0.0007
- Prev close
- 0.0001
- Mkt cap
- 0
- Vol
- 30.27K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.0001
- High
- 0.0001
- Forward P/E
- -0.02
- Beta
- 1.95
- Short ratio
- 0.74
- Inst. own
- 40.93%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Dec 29, 2022
- 50-d avg
- 0.134553
- 200-d avg
- 0.978319
- 1y target
- 3.08
1M chart
Signals (11)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Dec 21, 2022 | 3 years ago |
| SMA: Bullish | Dec 20, 2022 | 3 years ago |
| MACD: Sell Signal | Dec 8, 2022 | 3 years ago |
| SMA: Bearish | Dec 1, 2022 | 3 years ago |
| SMA: Bearish | Dec 1, 2022 | 3 years ago |
| SMA: Bullish | Nov 29, 2022 | 3 years ago |
| SMA: Bullish | Nov 29, 2022 | 3 years ago |
| MACD: Buy Signal | Nov 29, 2022 | 3 years ago |
| MACD: Sell Signal | Nov 28, 2022 | 3 years ago |
| SMA: Bearish | Nov 25, 2022 | 3 years ago |
| SMA: Bearish | Nov 25, 2022 | 3 years ago |
Analyst view
Consensus: hold
Hold
Price target (mean) 3.08 +3079900.0% upside
Now 0.0001
- Target (low)
- 0.16
- Target (mean)
- 3.08
- Target (high)
- 6.00
Ratings (0m) 4 3 buy · 1 hold · 0 sell
- Strong buy0
- Buy3
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 4
- 1 month ago 3
- 2 months ago 5
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.18 | -0.18 – -0.18 | -0.06 | -200.0% | 0 | 0.0% | 2 |
| Next quarter | -0.18 | -0.18 – -0.18 | -0.05 | -260.0% | 0 | 0.0% | 2 |
| Current year | -0.73 | -0.73 – -0.73 | -0.48 | -52.1% | 570.00K | -65.3% | 2 |
| Next year | -0.83 | -1.00 – -0.72 | -0.73 | -13.7% | 0 | 0.0% | 3 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 29, 2022 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Apr 29, 2022 | Stifel | Downgrade | Buy | Hold |
| Apr 6, 2021 | SVB Leerink | Maintained | — | Outperform |
| Feb 11, 2021 | Needham | Maintained | — | Buy |
| Nov 25, 2020 | Needham | Maintained | — | Buy |
| Nov 25, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 25, 2020 | SVB Leerink | Initiated | — | Outperform |
| Nov 25, 2020 | H.C. Wainwright | Initiated | — | Buy |
| Nov 25, 2020 | Cantor Fitzgerald | Initiated | — | Overweight |
| Nov 25, 2020 | Baird | Initiated | — | Outperform |
| Nov 25, 2020 | Needham | Upgrade | Hold | Buy |
| Nov 25, 2020 | Stifel Nicolaus | Downgrade | Buy | Hold |
| Nov 25, 2020 | Needham | Upgrade | Hold | Buy |
| Nov 25, 2020 | Needham | Downgrade | Buy | Hold |
| Nov 25, 2020 | Needham | Maintained | — | Buy |
| Nov 25, 2020 | PiperJaffray | Maintained | — | Overweight |
| Nov 25, 2020 | UBS | Initiated | — | Buy |
| Nov 25, 2020 | FBR Capital | Initiated | — | Outperform |
| Nov 25, 2020 | PiperJaffray | Initiated | — | Overweight |
| Nov 25, 2020 | Stifel Nicolaus | Maintained | — | Buy |
| Nov 25, 2020 | Needham | Initiated | — | Buy |
| Nov 25, 2020 | Stifel Nicolaus | Initiated | — | Buy |
| Nov 25, 2020 | Citigroup | Initiated | — | Buy |